Group 1 - The core viewpoint of the article is that the drug sac-TMT (TROP-2 ADC) from Kolun Botai Biopharmaceutical has received approval from the National Medical Products Administration for the treatment of HR-positive/HER2-negative breast cancer in the second line and above, marking the fourth indication approved for this drug in mainland China [1] - The drug has also been included in the national medical insurance catalog for the treatment of triple-negative breast cancer in the third line and EGFR mutation non-small cell lung cancer since January of this year [1] - Due to adjustments in the national medical insurance catalog pricing, the company has lowered its annual treatment cost assumptions for sac-TMT [1] Group 2 - The revenue forecasts for 2026 and 2027 have been reduced by 5% and 6% respectively [1] - The target price for the stock has been raised from HKD 470 to HKD 479, maintaining a "neutral" rating [1] - The business progress is in line with expectations but is offset by increasingly fierce competition [1]

格隆汇2月12日丨中牧股份(600195.SH)公布，公司于2026年2月11日收到陈章瑞先生的书面辞职报告， 陈章瑞先生因工作变动原因提出辞去公司董事、董事会战略与ESG委员会及董事会合规委员会成员职 务，辞职后不再担任公司任何职务。 ...

格隆汇2月12日丨腾景科技(688195.SH)在投资者互动平台表示，公司产品有少量直接出口欧盟国家。 ...

格隆汇2月12日丨德尔股份(300473.SZ)公布，公司拟根据募投项目建设安排及资金需求，使用不超 过7,270万元募集资金一次或分次逐步向全资子公司爱卓智能科技(上海)有限公司(简称"爱卓科技")和爱 卓智能科技(常州)有限公司(简称"常州爱卓")增资(含出资)或提供无息借款，用于实施"爱卓智能科技(常 州)有限公司汽车饰件等产品智能化改扩建项目(一期)"和"爱卓智能科技(常州)有限公司研发中心项目"。 增资(含出资)或借款的进度将根据募投项目的实际需求推进，借款期限自借款发放之日起至相关募投项 目实施完成之日，根据项目实施情况可到期后续借或提前还款。 ...

公司于2026年2月12日召开第三届董事会第二十次会议，审议通过《关于聘任公司总经理的议案》，同 意聘任常程先生为总经理，任期自本次董事会审议通过之日起至第三届董事会任期届满之日止。 格隆汇2月12日丨盛剑科技(603324.SH)公布，公司董事会于近日收到张伟明先生的书面辞职报告。张伟 明先生为更好地履行董事长职责，将更多精力投入到公司战略规划、规范治理等方面，辞去公司总经理 职务。辞去总经理职务后，张伟明先生仍将继续担任公司第三届董事会董事长及董事会相关专门委员会 委员等职。 ...

Core Viewpoint - Hanghua Co., Ltd. (688571.SH) reported a decline in both revenue and net profit for the fiscal year 2025, indicating challenges in the market environment and increased competition [1] Financial Performance - The company achieved an operating revenue of 1.249 billion yuan, a year-on-year decrease of 1.61% [1] - The net profit attributable to the parent company was 109 million yuan, down 21.97% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was approximately 99.49 million yuan, reflecting a 23.30% decline year-on-year [1] Operational Challenges - The primary reasons for the changes in operating performance include: 1. Overall slowdown in demand in the downstream printing market due to the broader market environment and international trade conditions, coupled with intensified market competition [1] 2. The newly acquired photolithography material project is still in the market cultivation stage and is currently operating at a loss [1] 3. Some fundraising projects have entered trial operation, leading to increased depreciation and operating costs [1]

Core Viewpoint - The company, Metro Design (003013.SZ), announced the resignation of Ms. Wang Jian from her positions as a director and a member of the remuneration and assessment committee due to work adjustments [1] Group 1 - Ms. Wang Jian submitted her resignation letter to the company's board recently [1] - Following her resignation, Ms. Wang will not hold any positions in the company or its subsidiaries [1] - Ms. Wang's original term was from October 30, 2024, to October 29, 2027 [1]

公司已与罗鸿先生签署了相关协议，对其应承担的保密义务和竞业限制义务作出了约定，其与公司不存 在涉及职务成果、知识产权纠纷或者潜在纠纷的情形。目前公司的技术研发和日常运营均正常稳健进 行，公司研发团队结构完整，后备人员充足，现有研发团队及核心技术人员能够支持公司核心在研管线 及创新产品的持续开发。本次核心技术人员的调整不会影响公司所拥有的核心技术及知识产权权属的完 整性，亦不会对公司的技术优势、核心竞争力和持续经营能力造成重大不利影响。 格隆汇2月12日丨首药控股(688197.SH)公布，公司核心技术人员HONGLUO(下称"罗鸿先生")近日因年 龄缘故提请退休。退休后，罗鸿先生将不再担任公司任何职务，公司不再认定其为核心技术人员。 ...

格隆汇2月12日丨中牧股份(600195.SH)在投资者互动平台表示，公司部分产品生产技术符合合成生物技 术特征。 ...

格隆汇2月12日丨腾景科技(688195.SH)在投资者互动平台表示，公司产品有少量直接出口欧盟国家。 ...